This experimental and computational study identifies promising inhibitors targeting Mycobacterium marinum β-carbonic anhydrase, suggesting potential for drug-resistant tuberculosis treatment.
Carbonic anhydrases in Mycobacterium tuberculosis are increasingly recognized as promising therapeutic targets in drug-resistant tuberculosis. In this study, a homology model of β-carbonic anhydrase was developed using the closely related Mycobacterium marinum sequence as a structural basis. A focused antituberculosis compound library was screened, identifying 2 ligands, F2686-0257 and F1011-1367, with strong binding affinities and distinct interaction patterns. Molecular dynamics simulations more than 100 ns confirmed stable backbones and conserved binding pockets, with F2686-0257 stabilized by aromatic anchoring and F1011-1367 by polar interactions. Structure-activity relationship analysis highlighted rigid aromatic scaffolds, controlled molecular size, and balanced polarity as favorable features. In M marinum growth assays, F2686-0257 inhibited bacterial proliferation at 100 µM and enhanced rifampicin activity, whereas F1011-1367 showed weaker inhibition without synergy. The compounds also showed favorable ADMET and drug-likeliness properties. These results support β-carbonic anhydrase as a viable target and provide scaffolds for the rational development of novel antitubercular agents.
No takes yet. Share an insight, caveat, or question.
Morshed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: